Pervasive Therapeutics of Cambridge, Massachusetts, has rounded up $12 million of venture capital in its second round. Much of that money will be used to pay for the clinical development of Pervasive's first product, a device for vascular disease. Pervasive develops therapies that combine biomaterials and drugs for more effective treatments. The company was founded by researchers from MIT and Harvard Medical School. Highland Capital Partners led the round.
- read this press release for more information